Skip to main content
SpringerLink
Log in

Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Goldman S, Geyer JR, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2013) A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol 114:173–179. doi:10.1007/s11060-013-1166-7

    Article  CAS  PubMed  Google Scholar 

  2. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2010) Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J clin oncol 28:4221–4227. doi:10.1200/JCO.2010.28.4687

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A (2013) Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol oncol 7:497–512. doi:10.1016/j.molonc.2013.01.001

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the Rally Foundation for Childhood Cancer Research in memory of Hailey Trainer and Dr. Ralph & Marian C. Falk Medical Research Trust for funding; Dr. Fernando A. Soares for scientific support, Dr. Olivier Delattre for providing the MON cells, Chiang-Ching Huang for statistical support and Abby L. Halpern for technical and editorial assistance.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Division of Pediatric Neurosurgery, Ann and Robert H. Lurie Children’s Hospital of Chicago, 225 E. Chicago Avenue, Box # 28, Chicago, IL, 60611, USA

    Simone Treiger Sredni, Kashyap Patel & Tadanori Tomita

  2. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Simone Treiger Sredni, Maria de Fátima Bonaldo & Tadanori Tomita

  3. AC Camargo Cancer Center, São Paulo, Brazil

    Felipe D’Almeida Costa

Authors
  1. Simone Treiger Sredni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kashyap Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe D’Almeida Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria de Fátima Bonaldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tadanori Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Treiger Sredni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sredni, S.T., Patel, K., Costa, F.D. et al. Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT. J Neurooncol 118, 201–203 (2014). https://doi.org/10.1007/s11060-014-1406-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1406-5

Keywords

Search

Navigation